arrow
S

Stefano Luminari

University of Modena and Reggio Emilia
H指数:53
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Newly diagnosed and relapsed follicular lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐up

新诊断和复发性滤泡性淋巴瘤:EHA 诊断、治疗和随访临床实践指南

2026-10-190
OA
Survival after first relapse in marginal zone lymphomas: Prospective data from the international observational NF10 study

边缘区淋巴瘤首次复发后的生存情况:国际观察性NF10研究的前瞻性数据

2026-09-060
OAAI
RENOIR phase 3 rituximab-lenalidomide vs rituximab as maintenance treatment in relapsed/refractory follicular lymphoma

RENOIR三期研究:利妥昔单抗-来那度胺对比利妥昔单抗作为复发/难治性滤泡性淋巴瘤的维持治疗

2026-09-010
PRE
Clonal hematopoiesis dynamics influences long-term outcomes of follicular lymphoma: Results from FIL FOLL12 trial

克隆性造血动态影响滤泡性淋巴瘤的长期结局:FIL FOLL12试验结果

2026-05-200
OAAI
Dynamics of complete responses (CRs) in patients with relapsed or refractory follicular lymphoma (R/R FL) treated with odronextamab in the ELM-2 study

奥德诺克单抗在ELM-2研究中对复发或难治性滤泡性淋巴瘤(R/R FL)患者完全缓解(CR)的动态分析

2026-04-160
OA
Genome-wide association study of event-free survival in follicular lymphoma patients treated with front-line immunochemotherapy

滤泡性淋巴瘤患者一线免疫化疗后的无事件生存期全基因组关联研究

2026-01-090
OAAI
Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trials

III期经典霍奇金淋巴瘤患者在接受2个ABVD疗程后,中期PET(PET-2)德瓦伊评分5分的患者:三项多中心试验的合并分析

2025-10-160
OA
Total Metabolic Tumor Volume Is a Strong Independent Prognostic Factor in Follicular Lymphomas: Results From a Sub-Study of the FOLL12 Trial

总代谢肿瘤体积是滤泡性淋巴瘤的一个强独立预后因素:FOLL12试验子研究的结果

2025-05-140
OA
Comparative Effectiveness of R-miniCOMP Versus R-miniCHOP in Older Non-Fit Patients With Diffuse Large B-Cell Lymphoma: Insights From a Fondazione Italiana Linfomi Cohort Study

R-miniCOMP与R-miniCHOP在老年非适合型弥漫大B细胞淋巴瘤患者中的比较疗效:来自意大利淋巴瘤基金会队列研究的见解

2025-05-130
PRE
Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma (vol 35, pg 1039, 2024)

奥德诺克单抗(odronextamab)在复发或难治性滤泡性淋巴瘤患者中的安全性与有效性(卷35,页1039,2024)

2025-03-011
PRE
Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi
2025-01-010
OA
Early progression beyond first-line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) study
2024-12-100
OAAI
Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)

Tafasitamab 联合 Lenalidomide 和 Rituximab 治疗复发或难治性滤泡性淋巴瘤:来自一项 3 期研究(inMIND)的结果

BLOOD
IF23.1
2024-11-253
PRE